Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate

J Affect Disord. 1996 Apr 26;38(1):67-9. doi: 10.1016/0165-0327(95)00095-x.

Abstract

We prolonged from 24 to 36 months a follow-up study of unipolar subjects with a high probability of recurrence treated with fluvoxamine (n = 32) or lithium (n = 32). During the extra observation period, two patients developed mania and were excluded from the study. There were no further recurrences in either the lithium or the fluvoxamine group. In our sample, previous prescriptions of tricyclics seem to predict a worse prognosis.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Antidepressive Agents, Tricyclic / adverse effects
  • Antidepressive Agents, Tricyclic / therapeutic use
  • Antimanic Agents / adverse effects
  • Antimanic Agents / therapeutic use*
  • Bipolar Disorder / diagnosis
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / psychology
  • Depressive Disorder / diagnosis
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / psychology
  • Female
  • Fluvoxamine / adverse effects
  • Fluvoxamine / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Lithium / adverse effects
  • Lithium / therapeutic use*
  • Male
  • Recurrence
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Antidepressive Agents, Tricyclic
  • Antimanic Agents
  • Lithium
  • Fluvoxamine